Biogen Stock Price, News & Analysis (NASDAQ:BIIB)

$313.97 -0.01 (0.00 %)
(As of 11/18/2017 09:06 AM ET)
Previous Close$313.97
Today's Range$316.00 - $310.18
52-Week Range$244.28 - $348.84
Volume826,600 shs
Average Volume1.54 million shs
Market Capitalization$66.39744 billion
P/E Ratio14.54
Dividend YieldN/A
Beta0.72

About Biogen (NASDAQ:BIIB)

Biogen logoBiogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.


Industry, Sector and Symbol:
  • Industry: Biopharmaceuticals
  • Sub-Industry: Biotechnology
  • Sector: Medical
  • Symbol: NASDAQ:BIIB
  • CUSIP: 09062X10
  • Web: www.biogen.com
Debt:
  • Debt-to-Equity Ratio: 0.46%
  • Current Ratio: 2.19%
  • Quick Ratio: 1.90%
Price-To-Earnings:
  • Trailing P/E Ratio: 14.54
  • Forward P/E Ratio: 14.25
  • P/E Growth: 1.96
Sales & Book Value:
  • Annual Sales: $11.4488 billion
  • Price / Sales: 5.80
  • Cash Flow: $23.64 per share
  • Price / Cash: 13.28
  • Book Value: $60.76 per share
  • Price / Book: 5.17
Profitability:
  • Trailing EPS: $16.31
  • Net Income: $3.7028 billion
  • Net Margins: 29.44%
  • Return on Equity: 38.51%
  • Return on Assets: 20.80%
Misc:
  • Employees: 7,400
  • Outstanding Shares: 211,480,000
 

Frequently Asked Questions for Biogen (NASDAQ:BIIB)

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) released its quarterly earnings results on Tuesday, October, 24th. The biotechnology company reported $6.31 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $5.70 by $0.61. The biotechnology company earned $3.08 billion during the quarter, compared to analyst estimates of $3.05 billion. Biogen had a return on equity of 38.51% and a net margin of 29.44%. The business's revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period in the previous year, the company posted $5.19 EPS. View Biogen's Earnings History.

When will Biogen make its next earnings announcement?

Biogen is scheduled to release their next quarterly earnings announcement on Thursday, January, 25th 2018. View Earnings Estimates for Biogen.

Where is Biogen's stock going? Where will Biogen's stock price be in 2017?

28 brokerages have issued twelve-month price objectives for Biogen's stock. Their forecasts range from $271.00 to $415.00. On average, they anticipate Biogen's stock price to reach $342.62 in the next twelve months. View Analyst Ratings for Biogen.

What are Wall Street analysts saying about Biogen stock?

Here are some recent quotes from research analysts about Biogen stock:

  • 1. Cantor Fitzgerald analysts commented, "MS franchise appears poised for modest negative growth. A tepid patient population growth rate combined with encroaching competition from new agents means existing franchise assets may have achieved peak revenues already, in our opinion." (10/24/2017)
  • 2. Citigroup Inc. analysts commented, "We're downgrading the stock to neutral from buy as we don't think the street fully appreciates Avexis competition and in coming 6-12 months we think MS pricing concerns in form of greater rebating get louder as we approach Gilenya losing patent and Celgene's Ozanimod launch," (10/23/2017)
  • 3. Stifel Nicolaus analysts commented, "gigantic" aducanumab phase 3 trial, which started in 2015 and was 50 percent enrolled in the second quarter of 2017, Shrader commented in his upgrade note. This should be seen as a "no news is good news" scenario as the Data and Safety Monitoring Board has likely seen a lot of data and hasn't reported anything negative.Second, Biogen's partner Eisai is set to report an interim outlook at its plaque-busting mAb that targets the form of Ab plaque thought to lead to neuronal destruction, the analyst continued. The only possible negative outcome would be strong plaque removal with no hints of cognitive benefit and any other result could either be very good or OK.Third, Biogen's often ignored stroke programs address a very large market. Of particular note, the company's Tysabri stoke program uncovered the "same cognitive and energy benefits in stroke patients that are routinely reported in MS patients" and turning this effect into a clinical endpoint that would be acceptable for the U.S. Food and Drug Administration is the likely next step.Finally, Ocrelizumab as part of the company's base business is "meh not mud," the analyst added. The therapy remains a drug with "remarkable anti inflammatory properties," but a commercial rollout will likely be "measured." (10/17/2017)
  • 4. Mizuho analysts commented, "We looked through early Spinraza data to draw as close to apples to apples comparison as possible. Here is a chart we found (from an old BIIB deck), which shows Spinraza increases SMN protein by ~2.7x." (10/2/2017)
  • 5. Cowen and Company analysts commented, "Biogen reported Q1 revenues of $2.81B (+3% Y/Y, vs. consensus of $2.74B) and non-." (4/25/2017)

Who are some of Biogen's key competitors?

Who are Biogen's key executives?

Biogen's management team includes the folowing people:

  • Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board (Age 68)
  • Michel Vounatsos, Chief Executive Officer, Director (Age 55)
  • Gregory F. Covino, Interim Principal Financial Officer, Chief Accounting Officer, Vice President - Finance (Age 51)
  • Ginger Gregory Ph.D., Chief Human Resource Officer, Executive Vice President (Age 49)
  • Kenneth A. Di Pietro, Executive Vice President - Human Resources (Age 58)
  • Susan H. Alexander Esq., Executive Vice President, Chief Legal Officer and Corporate Secretary (Age 60)
  • Michael D. Ehlers M.D., Ph.D., Executive Vice President, Head - Research and Development (Age 48)
  • Chirfi Guindo, Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation
  • Adriana Karaboutis, Executive Vice President - Technology , Business Solutions and Corporate Affairs (Age 54)
  • Jean-Paul Kress M.D., Executive Vice President, President - International and Head of Global Therapeutic Operations (Age 51)

Who owns Biogen stock?

Biogen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (1.10%), Ameriprise Financial Inc. (1.09%), Jackson Square Partners LLC (1.06%), Janus Henderson Group PLC (0.68%), Legal & General Group Plc (0.52%) and American Century Companies Inc. (0.43%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.

Who sold Biogen stock? Who is selling Biogen stock?

Biogen's stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., American Century Companies Inc., Swedbank, Prudential Financial Inc., Manning & Napier Advisors LLC, Westfield Capital Management Co. LP, First Quadrant L P CA and State of Tennessee Treasury Department. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, Brian S Posner, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Insider Buying and Selling for Biogen.

Who bought Biogen stock? Who is buying Biogen stock?

Biogen's stock was bought by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Bank of New York Mellon Corp, Assenagon Asset Management S.A., Jackson Square Partners LLC, Schroder Investment Management Group, State of Wisconsin Investment Board, Argent Capital Management LLC and Nomura Asset Management Co. Ltd.. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

How do I buy Biogen stock?

Shares of Biogen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biogen's stock price today?

One share of Biogen stock can currently be purchased for approximately $313.97.

How big of a company is Biogen?

Biogen has a market capitalization of $66.39744 billion and generates $11.4488 billion in revenue each year. The biotechnology company earns $3.7028 billion in net income (profit) each year or $16.31 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000.


MarketBeat Community Rating for Biogen (NASDAQ BIIB)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,162 (Vote Outperform)
Underperform Votes:  699 (Vote Underperform)
Total Votes:  1,861
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Biogen (NASDAQ:BIIB)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 10 Hold Ratings, 17 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.68)
Consensus Price Target: $342.62 (9.12% upside)

Consensus Price Target History for Biogen (NASDAQ:BIIB)

Price Target History for Biogen (NASDAQ:BIIB)

Analysts' Ratings History for Biogen (NASDAQ:BIIB)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/13/2017MizuhoSet Price TargetBuy$400.00N/AView Rating Details
11/9/2017Oppenheimer Holdings, Inc.Initiated CoverageOutperform$350.00 -> $350.00N/AView Rating Details
11/6/2017BMO Capital MarketsBoost Price TargetOutperform$381.00 -> $386.00N/AView Rating Details
10/27/2017Canaccord GenuityInitiated CoverageHold -> Hold$340.00N/AView Rating Details
10/25/2017HC WainwrightReiterated RatingBuy$340.00N/AView Rating Details
10/25/2017Royal Bank Of CanadaLower Price TargetSector Perform -> Sector Perform$315.00 -> $313.00N/AView Rating Details
10/24/2017SunTrust Banks, Inc.Reiterated RatingBuy$354.00N/AView Rating Details
10/24/2017Cantor FitzgeraldReiterated RatingHold$279.00N/AView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$402.00N/AView Rating Details
10/23/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$390.00N/AView Rating Details
10/23/2017Citigroup Inc.DowngradeBuy -> NeutralN/AView Rating Details
10/18/2017Bank of America CorporationBoost Price TargetBuy$358.00 -> $365.00N/AView Rating Details
10/17/2017Morgan StanleyReiterated RatingBuyN/AView Rating Details
10/17/2017Stifel NicolausUpgradeHold -> Buy$300.00 -> $415.00N/AView Rating Details
9/21/2017Raymond James Financial, Inc.DowngradeStrong-Buy -> Market Perform$244.28 -> $319.00LowView Rating Details
8/25/2017Robert W. BairdReiterated RatingHold$290.00LowView Rating Details
8/16/2017Goldman Sachs Group, Inc. (The)UpgradeBuy -> Conviction-Buy$338.00LowView Rating Details
7/27/2017Cowen and CompanyReiterated RatingBuyMediumView Rating Details
7/26/2017Deutsche Bank AGReiterated RatingBuy$315.00 -> $319.00LowView Rating Details
7/26/2017Leerink SwannReiterated RatingMarket Perform$304.00 -> $338.00HighView Rating Details
7/14/2017Credit Suisse GroupSet Price TargetHold$300.00LowView Rating Details
7/11/2017Jefferies Group LLCReiterated RatingHold -> Hold$310.00LowView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
5/25/2017Sanford C. BernsteinReiterated RatingOutperformLowView Rating Details
4/23/2017Barclays PLCReiterated RatingOverweight$380.00 -> $360.00MediumView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$223.03 -> $345.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageNeutralN/AView Rating Details
1/18/2017J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
8/2/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
6/8/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$344.00N/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Biogen (NASDAQ:BIIB)

Earnings by Quarter for Biogen (NASDAQ:BIIB)

Earnings History by Quarter for Biogen (NASDAQ BIIB)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/25/2018        
10/24/2017Q3 2017$5.70$6.31$3.05 billion$3.08 billionViewN/AView Earnings Details
7/25/2017Q2 2017$4.36$5.04$2.81 billion$3.08 billionViewN/AView Earnings Details
4/25/2017Q1 2017$4.97$5.20$2.73 billion$2.81 billionViewN/AView Earnings Details
1/26/2017Q416$4.96$5.04$2.94 billion$2.87 billionViewN/AView Earnings Details
10/26/2016Q316$4.97$5.19$2.91 billion$2.96 billionViewListenView Earnings Details
7/21/2016Q216$4.69$5.21$2.79 billion$2.89 billionViewListenView Earnings Details
4/21/2016Q116$4.47$4.79$2.75 billion$2.73 billionViewListenView Earnings Details
1/27/2016Q415$4.08$4.50$2.70 billion$2.84 billionViewListenView Earnings Details
10/21/2015Q315$3.80$4.48$2.65 billion$2.39 billionViewListenView Earnings Details
7/24/2015Q215$4.10$4.22$2.71 billion$2.59 billionViewListenView Earnings Details
4/24/2015Q115$3.91$3.82$2.66 billion$2.56 billionViewListenView Earnings Details
1/29/2015Q414$3.74$4.09$2.64 billion$2.60 billionViewListenView Earnings Details
10/22/2014Q3$3.22$3.80$2.48 billion$2.50 billionViewListenView Earnings Details
7/23/2014Q214$2.80$3.49$2.14 billion$2.42 billionViewListenView Earnings Details
4/23/2014Q114$2.56$2.47$2.00 billion$2.10 billionViewListenView Earnings Details
1/29/2014Q413$2.27$2.34$1.93 billion$2.00 billionViewListenView Earnings Details
10/28/2013Q313$2.10$2.35$1.78 billion$1.83 billionViewListenView Earnings Details
7/25/2013Q2 2013$1.93$2.30$1.62 billion$1.70 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.63$1.97$1.41 billion$1.40 billionViewListenView Earnings Details
1/28/2013Q4 2012$1.46$1.40$1.38 billion$1.40 billionViewListenView Earnings Details
10/25/2012$1.60$1.91ViewN/AView Earnings Details
7/24/2012$1.56$1.82ViewN/AView Earnings Details
5/1/2012$1.49$1.40ViewN/AView Earnings Details
1/31/2012$1.49$1.51ViewN/AView Earnings Details
10/28/2011$1.52$1.61ViewN/AView Earnings Details
7/26/2011$1.36$1.36ViewN/AView Earnings Details
4/21/2011$1.41$1.43ViewN/AView Earnings Details
2/1/2011$1.23$1.42ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Biogen (NASDAQ:BIIB)
2017 EPS Consensus Estimate: $20.42
2018 EPS Consensus Estimate: $24.46
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$4.47$5.03$4.75
Q2 20173$3.92$4.11$4.04
Q3 20174$5.69$6.16$5.92
Q4 20175$5.36$6.04$5.71
Q1 20183$5.77$6.13$5.96
Q2 20183$5.93$6.37$6.17
Q3 20183$6.04$6.24$6.17
Q4 20183$6.11$6.23$6.16
Q1 20191$6.30$6.30$6.30
Q2 20191$6.53$6.53$6.53
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Biogen (NASDAQ:BIIB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Biogen (NASDAQ BIIB)

Insider Ownership Percentage: 0.25%
Institutional Ownership Percentage: 88.35%
Insider Trades by Quarter for Biogen (NASDAQ:BIIB)
Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Insider Trades by Quarter for Biogen (NASDAQ BIIB)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/25/2017Susan H AlexanderEVPSell4,974$290.01$1,442,509.74View SEC Filing  
7/19/2017Susan H AlexanderEVPSell7,758$285.00$2,211,030.00View SEC Filing  
6/9/2017Brian S PosnerDirectorSell1,084$256.31$277,840.04View SEC Filing  
5/1/2017Michel VounatsosCEOBuy1,402$271.35$380,432.70View SEC Filing  
4/27/2017Alexander J. DennerDirectorBuy73,858$278.50$20,569,453.00View SEC Filing  
4/25/2017Paul J ClancyVPSell9,892$290.00$2,868,680.00View SEC Filing  
4/3/2017Alfred SandrockCMOSell1,981$274.08$542,952.48View SEC Filing  
3/13/2017Paul J ClancyVPSell9,891$291.55$2,883,721.05View SEC Filing  
2/27/2017Michel VounatsosCEOBuy1,333$285.39$380,424.87View SEC Filing  
1/9/2017Robert W PangiaDirectorSell5,450$295.39$1,609,875.50View SEC Filing  
10/4/2016Adriana KaraboutisEVPSell262$311.94$81,728.28View SEC Filing  
10/3/2016Adriana KaraboutisEVPSell380$313.00$118,940.00View SEC Filing  
9/22/2016Caroline DorsaDirectorSell27,570$314.00$8,656,980.00View SEC Filing  
7/21/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
6/6/2016Adam KoppelEVPSell555$290.00$160,950.00View SEC Filing  
6/3/2016George A ScangosCEOSell842$290.00$244,180.00View SEC Filing  
6/1/2016George A ScangosCEOSell3,855$289.74$1,116,947.70View SEC Filing  
5/25/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
5/2/2016George A ScangosCEOSell487$274.74$133,798.38View SEC Filing  
4/6/2016Adam KoppelEVPSell102$275.00$28,050.00View SEC Filing  
4/6/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
4/1/2016George A ScangosCEOSell487$258.83$126,050.21View SEC Filing  
3/1/2016George A ScangosCEOSell487$261.37$127,287.19View SEC Filing  
2/25/2016Adriana KaraboutisEVPSell84$261.90$21,999.60View SEC Filing  
2/25/2016Alfred SandrockCMOSell183$261.90$47,927.70View SEC Filing  
2/17/2016Alfred SandrockChief Medical OfficerSell722$256.16$184,947.52View SEC Filing  
2/17/2016George A ScangosCEOSell487$256.16$124,749.92View SEC Filing  
2/9/2016Alfred SandrockChief Medical OfficerSell852$246.54$210,052.08View SEC Filing  
12/4/2015Alfred SandrockCMOSell441$277.00$122,157.00View SEC Filing  
10/23/2015Alexander J DennerDirectorBuy310,000$277.47$86,015,700.00View SEC Filing  
7/27/2015Stelios PapadopoulosDirectorBuy10,000$304.88$3,048,800.00View SEC Filing  
6/19/2015Douglas E WilliamsEVPSell3,841$410.00$1,574,810.00View SEC Filing  
6/1/2015George A ScangosCEOSell1,362$398.87$543,260.94View SEC Filing  
4/1/2015George A ScangosCEOSell1,362$423.20$576,398.40View SEC Filing  
3/25/2015John CoxEVPSell12,010$449.06$5,393,210.60View SEC Filing  
3/20/2015Eric K RowinskyDirectorSell11,667$475.00$5,541,825.00View SEC Filing  
3/19/2015Eric K RowinskyDirectorSell2,333$436.14$1,017,514.62View SEC Filing  
3/17/2015Eric K RowinskyDirectorSell4,667$425.45$1,985,575.15View SEC Filing  
3/10/2015Robert W PangiaDirectorSell3,625$413.40$1,498,575.00View SEC Filing  
3/2/2015Alfred SandrockSVPSell3,174$409.49$1,299,721.26View SEC Filing  
2/17/2015Steven H HoltzmanEVPSell2,128$389.11$828,026.08View SEC Filing  
2/10/2015Alfred SandrockSVPSell1,143$398.11$455,039.73View SEC Filing  
2/2/2015Kenneth DipietroEVPSell1,656$389.03$644,233.68View SEC Filing  
12/15/2014Spyridon Artavanis-TsakonasSVPSell1,981$346.50$686,416.50View SEC Filing  
12/2/2014Steven H HoltzmanEVPSell1,749$335.65$587,051.85View SEC Filing  
11/11/2014Steven H HoltzmanEVPSell1,750$330.00$577,500.00View SEC Filing  
11/3/2014George A ScangosCEOSell1,128$320.78$361,839.84View SEC Filing  
10/1/2014George A ScangosCEOSell1,127$330.97$373,003.19View SEC Filing  
10/1/2014Steven H HoltzmanEVPSell1,750$330.97$579,197.50View SEC Filing  
8/1/2014George A ScangosCEOSell1,128$332.93$375,545.04View SEC Filing  
7/16/2014George A ScangosCEOSell12,316$312.37$3,847,148.92View SEC Filing  
5/19/2014Steven HoltzmanEVPSell1,221$289.15$353,052.15View SEC Filing  
5/1/2014George ScangosCEOSell2,123$285.56$606,243.88View SEC Filing  
4/17/2014Steven HoltzmanEVPSell1,221$291.00$355,311.00View SEC Filing  
4/1/2014George ScangosCEOSell2,123$308.42$654,775.66View SEC Filing  
4/1/2014Robert PangiaDirectorSell6,250$308.42$1,927,625.00View SEC Filing  
3/31/2014Brian PosnerDirectorSell3,000$296.76$890,280.00View SEC Filing  
3/20/2014Caroline DorsaDirectorSell10,000$348.88$3,488,800.00View SEC Filing  
3/19/2014Douglas WilliamsEVPSell3,505$352.29$1,234,776.45View SEC Filing  
3/17/2014Steven HoltzmanEVPSell1,221$334.83$408,827.43View SEC Filing  
3/11/2014Stuart KingsleyEVPSell8,428$336.83$2,838,803.24View SEC Filing  
3/3/2014George ScangosCEOSell2,942$335.79$987,894.18View SEC Filing  
2/26/2014Alfred SandrockSVPSell1,048$342.17$358,594.16View SEC Filing  
2/18/2014Steven HoltzmanEVPSell1,222$327.90$400,693.80View SEC Filing  
2/13/2014Kenneth DipietroEVPSell1,290$316.81$408,684.90View SEC Filing  
2/11/2014Alfred SandrockSVPSell2,085$314.31$655,336.35View SEC Filing  
2/11/2014George ScangosCEOSell2,456$314.31$771,945.36View SEC Filing  
2/4/2014Kenneth DipietroEVPSell1,655$299.01$494,861.55View SEC Filing  
1/21/2014Eric RowinskyDirectorSell2,020$310.09$626,381.80View SEC Filing  
1/15/2014Lynn SchenkDirectorSell1,000$297.48$297,480.00View SEC Filing  
1/8/2014William YoungDirectorSell15,000$285.11$4,276,650.00View SEC Filing  
1/6/2014Robert PangiaDirectorSell6,250$278.03$1,737,687.50View SEC Filing  
12/2/2013Lynn SchenkDirectorSell1,000$291.71$291,710.00View SEC Filing  
11/22/2013Raymond PawlickiSVPSell4,000$288.00$1,152,000.00View SEC Filing  
11/1/2013George A ScangosCEOSell2,239$245.57$549,831.23View SEC Filing  
11/1/2013Lynn SchenkDirectorSell1,000$245.00$245,000.00View SEC Filing  
10/22/2013Alfred SandrockSVPSell15,030$250.11$3,759,153.30View SEC Filing  
9/18/2013Paul ClancyCFOSell26,785$245.00$6,562,325.00View SEC Filing  
9/17/2013Steven HoltzmanEVPSell3,501$238.98$836,668.98View SEC Filing  
9/16/2013Paul ClancyCFOSell99,030$238.27$23,595,878.10View SEC Filing  
9/16/2013Raymond PawlickiSVPSell4,000$238.03$952,120.00View SEC Filing  
9/3/2013George ScangosCEOSell2,239$214.40$480,041.60View SEC Filing  
8/26/2013Douglas WilliamsEVPSell4,368$211.35$923,176.80View SEC Filing  
8/1/2013George A ScangosCEOSell2,239$218.82$489,937.98View SEC Filing  
7/16/2013George A ScangosCEOSell2,239$223.94$501,401.66View SEC Filing  
6/14/2013Alexander J DennerDirectorSell2,900$212.00$614,800.00View SEC Filing  
6/11/2013Brian S PosnerDirectorSell2,020$219.62$443,632.40View SEC Filing  
6/10/2013Lynn SchenkDirectorSell2,000$225.82$451,640.00View SEC Filing  
6/3/2013George A ScangosCEOSell1,598$234.16$374,187.68View SEC Filing  
6/3/2013Stephen A SherwinDirectorSell12,825$233.26$2,991,559.50View SEC Filing  
5/28/2013Robert W PangiaDirectorSell5,900$237.23$1,399,657.00View SEC Filing  
12/27/2012Alexander J DennerDirectorSell7,980$148.62$1,185,987.60View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Biogen (NASDAQ BIIB)

Source:
DateHeadline
Better Buy: Biogen Inc. vs. Gilead SciencesBetter Buy: Biogen Inc. vs. Gilead Sciences
www.fool.com - November 18 at 10:41 AM
Biogen Inc. (BIIB) Receives Consensus Recommendation of "Buy" from BrokeragesBiogen Inc. (BIIB) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 16 at 2:02 PM
If An Alzheimers Drug Succeeds, Could Our Health System Handle It?If An Alzheimer's Drug Succeeds, Could Our Health System Handle It?
finance.yahoo.com - November 16 at 12:00 PM
Biogen (BIIB) a Hold on Feeble Quant Score - Investorplace.comBiogen (BIIB) a Hold on Feeble Quant Score - Investorplace.com
investorplace.com - November 14 at 6:00 AM
Biogen Inc. (BIIB) Given a $400.00 Price Target by Mizuho AnalystsBiogen Inc. (BIIB) Given a $400.00 Price Target by Mizuho Analysts
www.americanbankingnews.com - November 13 at 5:12 PM
Biogen (BIIB) a Hold on Feeble Quant ScoreBiogen (BIIB) a Hold on Feeble Quant Score
investorplace.com - November 13 at 3:40 PM
Biogen Inc. (BIIB) Forecasted to Post FY2017 Earnings of $21.97 Per ShareBiogen Inc. (BIIB) Forecasted to Post FY2017 Earnings of $21.97 Per Share
www.americanbankingnews.com - November 13 at 3:58 AM
Brokers Set Expectations for Biogen Inc.s FY2021 Earnings (BIIB)Brokers Set Expectations for Biogen Inc.'s FY2021 Earnings (BIIB)
www.americanbankingnews.com - November 10 at 8:11 PM
BMO Capital Markets Increases Biogen Inc. (BIIB) Price Target to $386.00BMO Capital Markets Increases Biogen Inc. (BIIB) Price Target to $386.00
www.americanbankingnews.com - November 6 at 9:43 PM
BMO Capital Markets Increases Biogen Inc. (BIIB) Price Target to $386.00BMO Capital Markets Increases Biogen Inc. (BIIB) Price Target to $386.00
www.americanbankingnews.com - November 6 at 9:43 PM
Vapid Sales Growth Hamper Biogen (BIIB) RatingVapid Sales Growth Hamper Biogen (BIIB) Rating
investorplace.com - November 6 at 5:09 PM
Optimer Pharmaceuticals (OPTR) and Biogen (BIIB) Head-To-Head ReviewOptimer Pharmaceuticals (OPTR) and Biogen (BIIB) Head-To-Head Review
www.americanbankingnews.com - November 5 at 5:26 AM
Biogen (BIIB) & Syndax Pharmaceuticals (SNDX) Head to Head AnalysisBiogen (BIIB) & Syndax Pharmaceuticals (SNDX) Head to Head Analysis
www.americanbankingnews.com - November 4 at 5:46 PM
Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer’s Disease Treatment AducanumabBiogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
finance.yahoo.com - November 2 at 10:11 PM
Top Analyst Reports for Microsoft, Chevron & IntelTop Analyst Reports for Microsoft, Chevron & Intel
finance.yahoo.com - October 31 at 10:43 PM
Sales Growth Restricts Biogen (BIIB) RatingSales Growth Restricts Biogen (BIIB) Rating
investorplace.com - October 30 at 3:10 PM
Biogen Inc. to Post FY2020 Earnings of $26.70 Per Share, SunTrust Banks Forecasts (BIIB)Biogen Inc. to Post FY2020 Earnings of $26.70 Per Share, SunTrust Banks Forecasts (BIIB)
www.americanbankingnews.com - October 27 at 7:46 PM
Analysts Set Expectations for Biogen Inc.s Q4 2017 Earnings (BIIB)Analysts Set Expectations for Biogen Inc.'s Q4 2017 Earnings (BIIB)
www.americanbankingnews.com - October 27 at 12:54 PM
Biogen Inc. (BIIB) Forecasted to Earn FY2017 Earnings of $21.91 Per ShareBiogen Inc. (BIIB) Forecasted to Earn FY2017 Earnings of $21.91 Per Share
www.americanbankingnews.com - October 27 at 9:32 AM
A Look at Biogen’s Tecfidera in 3Q17A Look at Biogen’s Tecfidera in 3Q17
finance.yahoo.com - October 26 at 9:43 PM
How 3Q17 Shaped up for Tysabri, Fampyra, and ZinbrytaHow 3Q17 Shaped up for Tysabri, Fampyra, and Zinbryta
finance.yahoo.com - October 26 at 9:43 PM
Biogen Inc. to Post Q4 2017 Earnings of $5.36 Per Share, Jefferies Group Forecasts (BIIB)Biogen Inc. to Post Q4 2017 Earnings of $5.36 Per Share, Jefferies Group Forecasts (BIIB)
www.americanbankingnews.com - October 26 at 11:50 AM
William Blair Analysts Raise Earnings Estimates for Biogen Inc. (BIIB)William Blair Analysts Raise Earnings Estimates for Biogen Inc. (BIIB)
www.americanbankingnews.com - October 26 at 10:30 AM
Cantor Fitzgerald Comments on Biogen Inc.s FY2017 Earnings (BIIB)Cantor Fitzgerald Comments on Biogen Inc.'s FY2017 Earnings (BIIB)
www.americanbankingnews.com - October 26 at 10:28 AM
Leerink Swann Research Analysts Lift Earnings Estimates for Biogen Inc. (BIIB)Leerink Swann Research Analysts Lift Earnings Estimates for Biogen Inc. (BIIB)
www.americanbankingnews.com - October 26 at 10:28 AM
SunTrust Banks Comments on Biogen Inc.s FY2017 Earnings (BIIB)SunTrust Banks Comments on Biogen Inc.'s FY2017 Earnings (BIIB)
www.americanbankingnews.com - October 26 at 10:28 AM
Cramer's lightning round: There's no upside story for Kro...Cramer's lightning round: There's no upside story for Kro...
finance.yahoo.com - October 25 at 10:56 PM
FY2020 EPS Estimates for Biogen Inc. (BIIB) Cut by AnalystFY2020 EPS Estimates for Biogen Inc. (BIIB) Cut by Analyst
www.americanbankingnews.com - October 25 at 7:34 PM
Biogen: Analysis Of Q3 And Recent Events - Seeking AlphaBiogen: Analysis Of Q3 And Recent Events - Seeking Alpha
seekingalpha.com - October 25 at 5:56 PM
Biogen Q3 2017: Too Many Uncertainties - Seeking AlphaBiogen Q3 2017: Too Many Uncertainties - Seeking Alpha
seekingalpha.com - October 25 at 5:56 PM
Biogen Inc. (BIIB) Price Target Cut to $313.00 by Analysts at Royal Bank Of CanadaBiogen Inc. (BIIB) Price Target Cut to $313.00 by Analysts at Royal Bank Of Canada
www.americanbankingnews.com - October 25 at 8:03 AM
Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple SclerosisBiogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
finance.yahoo.com - October 25 at 4:35 AM
Biogen (BIIB) Earnings Growth Hampers Rating | InvestorPlace - Investorplace.comBiogen (BIIB) Earnings Growth Hampers Rating | InvestorPlace - Investorplace.com
investorplace.com - October 24 at 11:35 PM
Biogen shares rise 1.4% after Q3 profit, revenue beats - MarketWatchBiogen shares rise 1.4% after Q3 profit, revenue beats - MarketWatch
www.marketwatch.com - October 24 at 11:35 PM
Biogen Inc. Q3 Earnings Rise 25% - NasdaqBiogen Inc. Q3 Earnings Rise 25% - Nasdaq
www.nasdaq.com - October 24 at 11:35 PM
Biogen (BIIB) Tops Q3 Earnings & Sales, Spinraza Sales Up - NasdaqBiogen (BIIB) Tops Q3 Earnings & Sales, Spinraza Sales Up - Nasdaq
www.nasdaq.com - October 24 at 11:35 PM
3 Big Stock Charts for Tuesday: Biogen Inc (BIIB), Lockheed Martin Corporation (LMT) and McDonalds Corporation ... - Yahoo Finance3 Big Stock Charts for Tuesday: Biogen Inc (BIIB), Lockheed Martin Corporation (LMT) and McDonald's Corporation ... - Yahoo Finance
finance.yahoo.com - October 24 at 11:35 PM
Biogen Inc. (BIIB) Is Falling Despite Better Than Expected Q3 Results - NasdaqBiogen Inc. (BIIB) Is Falling Despite Better Than Expected Q3 Results - Nasdaq
www.nasdaq.com - October 24 at 11:35 PM
Edited Transcript of BIIB earnings conference call or presentation 24-Oct-17 12:30pm GMTEdited Transcript of BIIB earnings conference call or presentation 24-Oct-17 12:30pm GMT
finance.yahoo.com - October 24 at 11:35 PM
SunTrust Banks, Inc. Reaffirms Buy Rating for Biogen Inc. (BIIB)SunTrust Banks, Inc. Reaffirms Buy Rating for Biogen Inc. (BIIB)
www.americanbankingnews.com - October 24 at 9:58 PM
Biogen Inc. Q3 Earnings Rise 25%Biogen Inc. Q3 Earnings Rise 25%
www.rttnews.com - October 24 at 6:34 PM
Biogen profit beats Wall Street view on Spinraza salesBiogen profit beats Wall Street view on Spinraza sales
www.reuters.com - October 24 at 6:34 PM
Why Biogen May Sink Biotech StocksWhy Biogen May Sink Biotech Stocks
www.investopedia.com - October 24 at 6:34 PM
Biogen (BIIB) Q3 2017 Results - Earnings Call TranscriptBiogen (BIIB) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - October 24 at 6:34 PM
Biogen (BIIB) Beats on Q3 Earnings and RevenueBiogen (BIIB) Beats on Q3 Earnings and Revenue
finance.yahoo.com - October 24 at 6:34 PM
Biogens (BIIB) "Hold" Rating Reiterated at Cantor FitzgeraldBiogen's (BIIB) "Hold" Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - October 24 at 4:50 PM
Biogen Inc. (BIIB) to Post FY2021 Earnings of $26.45 Per Share, Leerink Swann ForecastsBiogen Inc. (BIIB) to Post FY2021 Earnings of $26.45 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - October 24 at 3:52 PM
Biogen Inc. (BIIB) Announces Quarterly  Earnings ResultsBiogen Inc. (BIIB) Announces Quarterly Earnings Results
www.americanbankingnews.com - October 24 at 8:54 AM
Biogen Bull Thesis Baked In, No Longer A Buy At Citi - BenzingaBiogen Bull Thesis Baked In, No Longer A Buy At Citi - Benzinga
www.benzinga.com - October 23 at 10:30 PM
Biogen (BIIB), Eisai Expand Pact to Develop and Commercialize Investigational Alzheimers Disease Treatments ... - StreetInsider.comBiogen (BIIB), Eisai Expand Pact to Develop and Commercialize Investigational Alzheimer's Disease Treatments ... - StreetInsider.com
www.streetinsider.com - October 23 at 10:30 PM

Social Media

Financials

Chart

Biogen (NASDAQ BIIB) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.